The Role of Adhesion Molecules in Multiple Myeloma
The DOI matches its Crossref record.
Abstract
The neoplastic plasma cells of multiple myeloma differ from normal plasma cells and other B-cell malignancies by an almost exclusive homing to the bone marrow microenvironment which clearly provides the appropriate support, both physical and cytokine, to mediate clonal proliferation and terminal differentiation. Cellular adhesion molecules are involved in the homing of malignant plasma cells to the bone marrow, the production of growth factors and the recirculation of these tumour cells in the advanced stages of disease. Neoplastic plasma cells express H-CAM (CD44), VLA-4 (CD49d/CD29), ICAM-1 (CD54), N-CAM (CD56) and LFA-3 (CD58). In addition VLA-5 (CD49e/ CD29) expression seems to be related to cells with less proliferative potential and more potential for paraprotein production. In addition there are fundamental changes in the bone marrow stroma of patients with multiple myeloma including altered composition of the extracellular matrix, increased growth capability of the cellular elements and increased synthesis of interleukin-6 and interleukin-3, which are features postulated to localise and promote growth of the circulating neoplastic progenitors in the bone marrow. However, the evidence to date does not fully explain the inter-relationship of the clonal B cells and the bone marrow stroma in patients with myeloma, including factors which trigger and facilitate the extravasation and recirculation of neoplastic plasma cells as seen in advanced disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., & Dalton, W. S. (1999) · Blood · doi:10.1182/blood.v93.5.1658 · Cited by 901
Multiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
Hurt, E. M., Wiestner, A., Rosenwald, A., Shaffer, A. L., Campo, E., Grogan, T., Bergsagel, P. L., Kuehl, W. M., & Staudt, L. M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00019-4 · Cited by 377
Bone marrow-derived mesenchymal stem cells and the tumor microenvironment
Bergfeld, S. A., & DeClerck, Y. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9222-7 · Cited by 345
Hazlehurst, L. A., Damiano, J. S., Buyuksal, I., Pledger, W. J., & Dalton, W. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203782 · Cited by 344
Hinz, M., Lemke, P., Anagnostopoulos, I., Hacker, C., Krappmann, D., Mathas, S., Dörken, B., Zenke, M., Stein, H., & Scheidereit, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020062 · Cited by 266
Hazlehurst, L. A., Landowski, T. H., & Dalton, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206943 · Cited by 203
Signaling Pathway Mediating Myeloma Cell Growth and Survival
Hideshima, T., & Anderson, K. C. (2021) · Cancers · doi:10.3390/cancers13020216 · Cited by 70
“For example, intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) on MM cells bind lymphocyte functionassociated antigen-1 (LFA-1) [8] and very late antigen (VLA-4) [9,10] on BMSCs, respectively.”
BackgroundMesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells
Norozi, F., Ahmadzadeh, A., Shahrabi, S., Vosoughi, T., & Saki, N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5187-7 · Cited by 69
Metadata
- Authors
- Cook, G., Dumbar, M., & Franklin, I. M.
- Venue
- Acta Haematologica
- Publisher
- S. Karger AG
- Published
- 2009-02-17
- Volume
- 97
- Issue
- 1-2
- Pages
- 81-89
- ISSN
- 0001-5792 (ISSN-L)
- 1421-9662
- OpenAlex
- W2134085733
- Cited by
- 53
- References
- 0
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.